|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||31.00 - 31.00|
|52 Week Range||19.50 - 36.06|
|Beta (5Y Monthly)||1.08|
|PE Ratio (TTM)||12.55|
|Forward Dividend & Yield||0.99 (3.21%)|
|Ex-Dividend Date||May 18, 2023|
|1y Target Est||8.23|
Key Insights Significant control over Fresenius SE KGaA by individual investors implies that the general public has...
German healthcare group Fresenius SE lifted its earnings target for generic hospital drugs unit Kabi, citing demand for blood plasma products and clinical nutrition and the planned launches of generic biotech drugs in the United States. Kabi's 2023 sales, adjusted for currency swings, would likely grow by a "mid-single-digit" percentage, where it had previously predicted a "low-to mid-single-digit" gain, Fresenius said ahead of an investor event on Thursday. It is now targeting an operating profit margin over sales of about 14%, up from about 13% seen previously.
Investing.com -- With a price increase of 1.30%, Fresenius shares (ETR:FREG) ranked second in the German benchmark DAX index on Thursday. Positive share price impetus was provided by a capital market day in London centered around its pharmaceuticals and medical technology subsidiary Kabi.
Fresenius SE & Co. KGaA ( ETR:FRE ) is about to trade ex-dividend in the next three days. Typically, the ex-dividend...
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Q4 2022 Cara Therapeutics Inc Earnings Call
FRANKFURT (Reuters) -German healthcare group Fresenius SE will slash costs and proceed with plans to cede strategic control over struggling dialysis group Fresenius Medical Care (FMC) as its new CEO seeks to simplify the diversified healthcare group, it said. The move comes after Elliott Investment Management took a stake in Fresenius last year, sparking speculation the activist investor might push for a break-up of the company. "This is an inflection point for Fresenius," Chief Executive Michael Sen said on Tuesday.
German healthcare group Fresenius SE will slash costs and proceed with plans to cede strategic control over struggling dialysis group Fresenius Medical Care (FMC) as its new CEO seeks to simplify the diversified healthcare group, it said. The move comes after Elliott Investment Management took a stake in Fresenius last year, sparking speculation the activist investor might push for a break-up of the company. "This is an inflection point for Fresenius," Chief Executive Michael Sen said on Tuesday.
German healthcare group Fresenius SE said on Thursday it was potentially ready to cede control over Fresenius Medical Care (FMC), after a fall in earnings at the world's largest dialysis company. Shares in FMC were down 3.4% at 1538 GMT, while Fresenius stock surged 4.3% after it said it was considering de-consolidating the subsidiary, meaning its sales would no longer be fully integrated into its financial reports. Elliott Investment Management took a stake in Fresenius SE in October, a person familiar with the matter told Reuters at the time, sparking speculation the activist investor might push for a break up of the diversified healthcare company.
Today we will run through one way of estimating the intrinsic value of Fresenius SE & Co. KGaA ( ETR:FRE ) by...
While it may not be enough for some shareholders, we think it is good to see the Fresenius SE & Co. KGaA ( ETR:FRE...
Every investor in Fresenius SE & Co. KGaA ( ETR:FRE ) should be aware of the most powerful shareholder groups. We can...
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Fresenius SE & Co. KGaA ( ETR:FRE ) saw a significant share price rise of over 20% in the past couple of months on the...
Fresenius SE KGaA ( ETR:FRE ) Third Quarter 2022 Results Key Financial Results Revenue: €10.5b (up 12% from 3Q 2021...
What are the early trends we should look for to identify a stock that could multiply in value over the long term...
German healthcare group Fresenius has cut its 2022 guidance for the second time on persistent cost inflation and staff shortages with its new CEO pledging a review of all its diversified businesses. The company's shares gained 5.7% on Monday, bouncing back from a drop on Friday, on hopes that a new leadership team will right the ship. In a statement on Sunday, the drugmaker and healthcare services company said its adjusted net income would likely fall 10% this year, excluding foreign exchange effects, having previously indicated a decline in a "single-digit percentage range" at worst.
Newly appointed Fresenius CEO Michael Sen said that the company's debt-financed growth strategy cannot continue, in an interview in Frankfurter Allgemeine Zeitung's Wednesday edition. Regarding Elliott Investment Management's stake in the company announced last week, Sen said: "We have already been in contact with Elliott." Fresenius management will include the opinion of investors regarding the future of the company in its considerations, he said, adding that no banks had been mandated for the sale of its hospital operator Helios.
FRANKFURT (Reuters) -Elliott Investment Management has taken a stake in Fresenius SE, a person familiar with the matter told Reuters on Wednesday, sparking speculation the activist investor might push for a break up of the diversified healthcare company. Fresenius and Elliott were not immediately available for comment. Shares in Fresenius, which is controlled by charitable trust Else Kroener Fresenius-Stiftung, were up 9% at 1202 GMT.
The world’s largest dialysis company is seeking out kidney disease patients long before they need the most acute form of care as it plans for growth of new drugs that attack the condition’s causes early on. For decades, Germany's Fresenius Medical Care (FMC) has been the biggest player in the $50 billion U.S. market providing dialysis and related machines that help filter out blood toxins for people whose kidneys have failed to function. The company’s 17.6 billion euros ($17.6 billion) in annual revenue has been sustained for decades by high rates of obesity and diabetes, which contribute to kidney damage.
FRANKFURT (Reuters) -Fresenius SE said its long-serving Chief Executive Stephan Sturm would quit, to be replaced by the head of its drugs unit, after the diversified group's earnings were hit following the COVID pandemic and a surge in costs. Michael Sen, a former management board member of Siemens and finance chief of E.ON, who now runs hospital drugs division Kabi, will take the helm on Oct. 1, the company said on Friday. Stephan Sturm, finance chief since 2005 and CEO since 2016, would leave the company "on good terms", it said in a statement, without giving a reason for his departure.
(Reuters) -Shares in the world's largest kidney dialysis provider Fresenius Medical Care (FMC) plunged more than 12% to a 12-year low on Thursday after it cut its earnings outlook as costs surge and a U.S. staff shortage leaves it scrambling for nurses. In an unscheduled statement late on Wednesday, FMC flagged a decline in net income approaching 20% this year and withdrew its 2025 targets. Most of its U.S. patients are covered by state-run insurer Medicare, with lump-sum reimbursements per patient that only get adjusted to cost inflation with a two-year delay, the chief executive of FMC parent Fresenius, Stephan Sturm, said on an analyst call.
The heavy selling pressure might have exhausted for Fresenius (FMS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.